These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8833886)

  • 1. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes.
    Visentin GP; Malik M; Cyganiak KA; Aster RH
    J Lab Clin Med; 1996 Oct; 128(4):376-83. PubMed ID: 8833886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
    Ahmad S; Haas S; Hoppensteadt DA; Lietz H; Reid U; Bender N; Messmore HL; Misselwitz F; Bacher P; Gaikwad BS; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2002 Oct; 108(1):49-55. PubMed ID: 12586132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.
    Visentin GP; Ford SE; Scott JP; Aster RH
    J Clin Invest; 1994 Jan; 93(1):81-8. PubMed ID: 8282825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the patient population on the risk for heparin-induced thrombocytopenia.
    Warkentin TE; Sheppard JA; Horsewood P; Simpson PJ; Moore JC; Kelton JG
    Blood; 2000 Sep; 96(5):1703-8. PubMed ID: 10961867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
    Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG
    Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin.
    Griffin JW; Hopkinson WJ; Lassen MR; Thethi I; Litinas E; Fareed J
    Clin Appl Thromb Hemost; 2011; 17(6):567-71. PubMed ID: 22345625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis.
    Warkentin TE; Sheppard JI; Sun JC; Jung H; Eikelboom JW
    J Thromb Haemost; 2013 Feb; 11(2):253-60. PubMed ID: 23216710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population.
    Mullen MP; Wessel DL; Thomas KC; Gauvreau K; Neufeld EJ; McGowan FX; Dinardo JA
    Anesth Analg; 2008 Aug; 107(2):371-8. PubMed ID: 18633010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
    Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.
    Lubenow N; Hinz P; Thomaschewski S; Lietz T; Vogler M; Ladwig A; Jünger M; Nauck M; Schellong S; Wander K; Engel G; Ekkernkamp A; Greinacher A
    Blood; 2010 Mar; 115(9):1797-803. PubMed ID: 19965682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.
    Selleng S; Malowsky B; Itterman T; Bagemühl J; Wessel A; Wollert HG; Warkentin TE; Greinacher A
    Am Heart J; 2010 Aug; 160(2):362-9. PubMed ID: 20691844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.
    Pouplard C; May MA; Iochmann S; Amiral J; Vissac AM; Marchand M; Gruel Y
    Circulation; 1999 May; 99(19):2530-6. PubMed ID: 10330384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.
    Walenga JM; Jeske WP; Prechel MM; Bacher P; Bakhos M
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():69-80. PubMed ID: 15085468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the humoral immune response in heparin-induced thrombocytopenia.
    Suh JS; Malik MI; Aster RH; Visentin GP
    Am J Hematol; 1997 Mar; 54(3):196-201. PubMed ID: 9067497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients.
    Boonyawat K; Angchaisuksiri P; Aryurachai K; Chaiyaroj S; Ahmadi Z; Chong BH
    Thromb Res; 2014 Nov; 134(5):957-62. PubMed ID: 25204999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery.
    Everett BM; Yeh R; Foo SY; Criss D; Van Cott EM; Laposata M; Avery EG; Hoffman WD; Walker J; Torchiana D; Jang IK
    Ann Thorac Surg; 2007 Feb; 83(2):592-7. PubMed ID: 17257993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up.
    Mattioli AV; Bonetti L; Zennaro M; Ambrosio G; Mattioli G
    Am Heart J; 2009 Mar; 157(3):589-95. PubMed ID: 19249435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.
    Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A
    Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.